Table 3. Effect of AVE8134 and rosiglitazone in male ZDF rats on food consumption during 8 weeks treatment. Glycemic index (GI) after 2 weeks treatment, calculated as AUC of blood glucose during oGTT. Non-fasted insulin before and after treatment. Safety parameter: serum activity of transaminases (AST and ALT) and alkaline phosphatase (AP) after 8 weeks treatment. bP<0.05 vs obese control.
| Lean control | Obese control | AVE8134 10 mg/kg | Food restricted | Rosiglitazone 3 mg/kg | ||
|---|---|---|---|---|---|---|
| Food consumption (g·animal−1·d−1) | 21±0.3 | 41±1.3 | 29±0.8b | 30±1.4b | 44±1.3 | |
| Age/treatment (week) | ||||||
| Insulin (μg/L) | 7/0 | 0.41±0.01 | 11.46±1.89 | 13.44±3.29 | 10.30±1.24 | 9.17±1.28 |
| 9/2 | 0.56±0.07 | 3.87±0.33 | 3.84±0.36 | 10.30±1.31 | 4.79±0.54 | |
| 13/6 | 0.76±0.12 | 2.68±0.24 | 5.17±0.39 | 11.32±3.07 | 7.29±1.24 | |
| 15/8 | <0.40 | 1.08±0.37 | 0.44±0.11 | 1.93±0.51 | 2.64±0.68 | |
| AUC oGTT (mmol·L−1·min) | 272±24 | 1541±50 | 601±30 | 954±137 | 663±100 | |
| AST (U/L) | 135±4 | 109±8 | 125±9 | 151±17 | 105±4 | |
| ALT (U/L) | 52±2 | 102±10 | 42±4 | 149±30 | 81±3 | |
| AP (U/L) | 87±2 | 253±13 | 990±52 | 223±11 | 156±33 |